Currently, there are increasing trends for the application in mass-forming cancers by focusing on HER2 or HER3 including zanidatamab, the biparatopic HER2 targeting antibody, and zenocutuzumab (Zeno) which exerts anti-cancer activity by targeting HER2 and HER3 respectively. The gene discussed is ERBB3; the disease is cancer.